These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21372353)

  • 21. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy.
    Horsmans Y; Solbreux PM; Daenens C; Desager JP; Geubel AP
    Aliment Pharmacol Ther; 1997 Feb; 11(1):165-70. PubMed ID: 9042989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
    Flamm SL
    Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spectral electroencephalogram in liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy.
    Singh J; Sharma BC; Maharshi S; Puri V; Srivastava S
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1203-9. PubMed ID: 26716736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
    Saboo K; Shamsaddini A; Iyer MV; Hu C; Fagan A; Gavis EA; White MB; Fuchs M; Heuman DM; Sikaroodi M; Iyer RK; Gillevet PM; Bajaj JS
    J Hepatol; 2021 Jan; 74(1):80-88. PubMed ID: 32679299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis.
    Shen YC; Chang YH; Fang CJ; Lin YS
    Nutr J; 2019 Jul; 18(1):34. PubMed ID: 31279342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durability of rifaximin response in hepatic encephalopathy.
    Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
    J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial.
    Wang JY; Bajaj JS; Wang JB; Shang J; Zhou XM; Guo XL; Zhu X; Meng LN; Jiang HX; Mi YQ; Xu JM; Yang JH; Wang BS; Zhang NP
    J Dig Dis; 2019 Oct; 20(10):547-556. PubMed ID: 31448533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis.
    Sharma P; Sharma BC; Sarin SK
    Liver Int; 2009 Oct; 29(9):1365-71. PubMed ID: 19555401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose.
    Sharma P; Agrawal A; Sharma BC; Sarin SK
    J Gastroenterol Hepatol; 2011 Jun; 26(6):996-1003. PubMed ID: 21129028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
    Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
    Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding.
    Aires FT; Ramos PT; Bernardo WM
    Rev Assoc Med Bras (1992); 2016; 62(3):243-7. PubMed ID: 27310548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal treatment of hepatic encephalopathy.
    Waghray A; Waghray N; Kanna S; Mullen K
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy].
    Abdo-Francis JM; Pérez-Hernández JL; Hinojosa-Ruiz A; Hernández-Vásquez JR
    Rev Gastroenterol Mex; 2010; 75(2):135-41. PubMed ID: 20615780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.
    Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J
    Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic Encephalopathy Is Associated with Persistent Learning Impairments Despite Adequate Medical Treatment: A Multicenter, International Study.
    Nardelli S; Allampati S; Riggio O; Mullen KD; Prakash R; Gioia S; Unser A; White MB; Fagan AC; Wade JB; Farcomeni A; Gavis EA; Bajaj JS
    Dig Dis Sci; 2017 Mar; 62(3):794-800. PubMed ID: 28039670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy.
    Prasad S; Dhiman RK; Duseja A; Chawla YK; Sharma A; Agarwal R
    Hepatology; 2007 Mar; 45(3):549-59. PubMed ID: 17326150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Barriers to Lactulose Adherence in Patients with Cirrhosis and Hepatic Encephalopathy.
    Chow KW; Ibrahim BM; Yum JJ; Dang A; Dang L; Chen KT; Jackson NJ; Saab S
    Dig Dis Sci; 2023 Jun; 68(6):2389-2397. PubMed ID: 37119376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
    Higuera-de-la-Tijera F; Servín-Caamaño AI; Salas-Gordillo F; Pérez-Hernández JL; Abdo-Francis JM; Camacho-Aguilera J; Alla SN; Jiménez-Ponce F
    Can J Gastroenterol Hepatol; 2018; 2018():3015891. PubMed ID: 30079329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy.
    Abd-Elsalam S; El-Kalla F; Elwan N; Badawi R; Hawash N; Soliman S; Soliman S; Elkhalawany W; ElSawaf MA; Elfert A
    J Clin Gastroenterol; 2019 Mar; 53(3):226-230. PubMed ID: 29668561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
    Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.